Skip to main content
ELI LILLY & Co logo

ELI LILLY & Co — Investor Relations & Filings

Ticker · LLY ISIN · US5324571083 LEI · FRDRIPF3EKNDJ2CQJL29 US Manufacturing
Open in API
Filings indexed 3,870 across all filing types
Latest filing 2019-03-11 M&A Activity
Country US United States of America
Listing US LLY

About ELI LILLY & Co

https://www.lilly.com/

Eli Lilly and Company is a global, research-based medicine company that discovers, develops, manufactures, and sells pharmaceutical products. The company focuses on creating treatments in key therapeutic areas, including diabetes, obesity, immunology, oncology, and neuroscience. Leveraging biotechnology and chemistry, it develops medicines for some of the world's most significant health challenges. Historically known for the commercialization of insulin, the company continues to be a major provider of therapies for chronic diseases. Its stated purpose is to unite caring with discovery to create medicines that make life better for people around the world.

Recent filings

Filing Released Lang Actions
SC TO-I/A Filing
M&A Activity Classification · 100% confidence The document is a Schedule TO filing, specifically an Amendment No. 4 to a Tender Offer Statement under Rule 14d-100 and Rule 13e-4 of the Securities Exchange Act of 1934. It relates to an issuer tender offer by Eli Lilly and Company to exchange shares of common stock with Elanco Animal Health Incorporated. The document includes detailed terms of the transaction, preliminary results of the exchange offer, and exhibits related to the tender offer process. It is not a financial report, earnings release, or management discussion but a regulatory filing related to a tender offer transaction. Therefore, it fits best under the category of M&A Activity (TAR) filings, which cover announcements and documents related to merger proposals or takeover bids, including tender offers.
2019-03-11 English
425 Filing
Merger & Acquisition Classification · 95% confidence The document is filed by Eli Lilly and Company pursuant to Rule 425 under the Securities Act of 1933, which relates to communications in connection with a merger or acquisition transaction. The text describes an exchange offer by Eli Lilly to exchange shares of Elanco Animal Health for shares of Lilly common stock. It includes detailed terms of the exchange offer, indicative exchange ratios, VWAP data, and references to a Prospectus. The document is a communication related to a merger or acquisition transaction, specifically an exchange offer, and is filed under Rule 425, which is a type of merger communication. This fits the category of Merger & Acquisition filings (MA), which include merger communications such as Form 425 filings. The document is not an announcement of a report, nor is it a full annual or quarterly report, nor a regulatory filing or certification. It is a detailed filing related to a merger transaction.
2019-03-08 English
425 Filing
M&A Activity Classification · 95% confidence The document is a press release by Eli Lilly and Company announcing the final exchange ratio for an exchange offer involving shares of Lilly common stock and Elanco common stock. It references the Securities Act of 1933 Rule 425, which pertains to communications related to merger or acquisition transactions. The content focuses on the terms and details of the exchange offer, including the ratio, expiration date, and dealer managers. There is no financial statement, quarterly or annual report, or detailed financial analysis present. The document is an announcement related to a merger/acquisition transaction, specifically an exchange offer, which fits the category of M&A Activity (TAR). The document length is over 7000 characters, so it is not a brief notice or a report publication announcement. Therefore, the appropriate classification is M&A Activity (TAR) with high confidence.
2019-03-07 English
SC TO-I/A Filing
M&A Activity Classification · 95% confidence The document is a Schedule TO (Tender Offer Statement) filed with the SEC by Eli Lilly and Company. It references Rule 14d-100 and Rule 13e-4 under the Securities Exchange Act of 1934, indicating it is related to a tender offer transaction. The document includes detailed terms of the transaction, exhibits such as prospectuses, letters of transmittal, and press releases related to the exchange offer. It is an amendment to a tender offer statement, which is a regulatory filing related to M&A activity but is not itself a merger proxy statement or tender offer communication form like DEFM14A or SC TO-*. The document is lengthy (15,000 characters) and contains substantive transaction details, not just an announcement or certification. Given the nature of the filing and the SEC form type (Schedule TO), the most appropriate classification is M&A Activity (TAR), which covers announcements and documents related to merger proposals or takeover bids, including tender offer statements.
2019-03-07 English
425 Filing
M&A Activity Classification · 95% confidence The document is filed pursuant to Rule 425 under the Securities Act of 1933, which relates to communications in connection with a merger or acquisition transaction. The text describes an exchange offer by Eli Lilly and Company to exchange shares of Elanco Animal Health Incorporated for shares of Lilly common stock. It includes detailed terms of the exchange offer, indicative exchange ratios, VWAP data, and references to a Prospectus. The document is not a full financial report, earnings release, or management discussion, but rather a communication related to a merger/takeover transaction. Rule 425 filings are typically considered part of merger and acquisition activity disclosures. Therefore, the document fits best under the category for M&A Activity (Code: TAR). The document length is substantial and contains detailed information about the exchange offer, not just an announcement or a brief notice, so it is not a Report Publication Announcement or Regulatory Filing. Confidence is high given the clear references to Rule 425 and the nature of the content.
2019-03-07 English
425 Filing
Merger & Acquisition Classification · 95% confidence The document is filed by Eli Lilly and Company pursuant to Rule 425 under the Securities Act of 1933, which relates to communications in connection with a merger or acquisition transaction. The text describes an exchange offer by Eli Lilly to exchange shares of Elanco Animal Health for shares of Lilly common stock. It includes detailed terms of the exchange offer, the exchange ratio, conditions, and related information such as prospectus and press releases. The document is not a full annual or quarterly report, nor is it a simple announcement or certification. It is a communication related to a merger/acquisition transaction, specifically an exchange offer, which fits the category of Merger & Acquisition filings. The document length is substantial (15,000 characters), indicating it is the actual communication text, not just a brief announcement or notice. Therefore, the appropriate classification is Merger & Acquisition (MA).
2019-03-07 English

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.